Page 12 - சிங்கப்பூர் தேமாஸேக் ஹோல்டிங்ஸ் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Centurium-led consortium completes $4.76b take-private deal of China Biologic April 22, 2021 Nasdaq-listed biopharmaceutical firm China Biologic Products Holdings suspended the trading of its shares on Wall Street on Wednesday, after the completion of a take-private deal sponsored by a Chinese buyout group that valued the firm at about $4.76 billion. The consortium is led by entities affiliated with Centurium Capital, a private equity (PE) firm founded by former Warburg Pincus partner David Li. Other investors in the consortium include Chinese PE company CITIC Capital; Asia-focused Hillhouse Capital; and V-Sciences Investments, a subsidiary of Singapore’s Temasek Holdings, among others. China Biologic signed the deal in November 2020, in which the investors had agreed to pay $120 per share in cash to privatise the firm through its merger with CBPO Group Limited. China Biologic will cease to be a publicly-traded company as a result of the deal.

David liWarburg pincusDavid gaoChina biologic products holdingsChina group investmentSingapore temasek holdingsGl capital groupWall streetCenturium capitalAsia focused hillhouse capitalV sciences investmentsTemasek holdingsChina biologicMedical applianceடேவிட் லிவார்பர்க் பிங்கஸ்